Inventiva S.A. ADR (IVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IVA Stock Summary
- Of note is the ratio of INVENTIVA SA's sales and general administrative expense to its total operating expenses; just 6.81% of US stocks have a lower such ratio.
- IVA's price/sales ratio is 17.42; that's higher than the P/S ratio of 93.88% of US stocks.
- As for revenue growth, note that IVA's revenue has grown 57.39% over the past 12 months; that beats the revenue growth of 86.81% of US companies in our set.
- Stocks that are quantitatively similar to IVA, based on their financial statements, market capitalization, and price volatility, are ARAV, IMMP, ACIU, ABUS, and HGEN.
- IVA's SEC filings can be seen here. And to visit INVENTIVA SA's official web site, go to www.inventivapharma.com.
IVA Stock Price Chart Interactive Chart >
IVA Price/Volume Stats
| Current price | $3.65 | 52-week high | $12.15 |
| Prev. close | $3.76 | 52-week low | $3.49 |
| Day low | $3.65 | Volume | 9,146 |
| Day high | $3.80 | Avg. volume | 8,174 |
| 50-day MA | $5.36 | Dividend yield | N/A |
| 200-day MA | $5.13 | Market Cap | 153.79M |
Inventiva S.A. ADR (IVA) Company Bio
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Latest IVA News From Around the Web
Below are the latest news stories about INVENTIVA SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.
Inventiva GAAP EPS of -€1.31 misses by €0.02, revenue of €12.18M misses by €0.44M
|
Inventiva reports its 2022 full-year resultsCash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹ upfront payment Inventiva recei |
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial ResultsDaix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, |
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022. Preliminary Financial Resu |
Inventiva reports preliminary financial results for Full-Year 2022¹Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022. Preliminary Financial Resu |
IVA Price Returns
| 1-mo | -28.57% |
| 3-mo | -18.16% |
| 6-mo | -7.20% |
| 1-year | -67.98% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.16% |
| 2022 | -67.35% |
| 2021 | -5.79% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...